Illinois Court Denies Motion to Dismiss and Motion to Strike or Deny Class Allegations Against MSP Recovery

Another shot was fired in the ongoing battle between MSP Recovery LLC and insurers. On July 13, 2018 an Illinois District Court denied two motions brought by State Farm, one to dismiss based on the Second Amended Complaint and a second to strike or deny class allegations.

As we recently reported, MSP Recovery was recently slapped on the wrist by the Illinois Court regarding standing in another action the law firm brought against State Farm. In Recovery v. State Farm Mut. Auto. Ins. Co., MSP Recovery appears to have regained a small win.

Attempting to build off of their recent win, State Farm alleged that MSP Recovery lacked standing, or in the alternative, that Plaintiffs have failed to state a claim upon which relief can be granted. More specifically, State Farm brought a factual challenge to standing, arguing that Plaintiffs did not hold valid assignments from Medicare Advantage Organizations.

State Farm disputed that Plaintiffs held valid assignments to pursue rights of recovery under the Medicare Secondary Payer Act (MSP) provisions. In support of this argument, Plaintiffs contended that Florida Healthcare Plus (FHP), an HMO with appropriate standing, assigned its right of recovery under the MSP to La Ley Recovery (LLR) which then assigned its rights of recovery to MSP Recovery. A second assignee, SummaCare, was also alleged to have assigned its right of reimbursement as well. However, the Court found ultimately this agreement could not confer standing as, interestingly, documentation assigning such right was signed after[1] the claim was filed. Regardless, the Court disagreed with State Farm.

Referring to a document titled “Recovery Agreement” the Court found intent by FHP to transfer claims under the MSP to La Ley Recovery (LLR) which in turn assigned its rights to MSP Recovery LLC. The Court did note that the agreement between FHP and LLR required any assignee must be approved by FHP. This was shown through settlement agreements between FHP and some of the Plaintiffs.

State Farm then attempted to argue that even if valid assignments existed, no injuries were suffered to the exemplar beneficiary in this matter. State Farm contended that they had notified CMS of the injury to a representative beneficiary and then paid a series of medical bills under that representative beneficiary’s car insurance policy which then exhausted the policy coverage limits. The Court noted that according to 42. C.F.R § 411.24(i), a “primary payer must reimburse Medicare even though it has already reimbursed the beneficiary or other party.” As payments were not made to FHP/LLR standing in the place of the Agency, the court found a question as to whether an injury was suffered. And as the court “need only find that one plaintiff has standing to permit the case to go forward” the motion was denied. As such, the Court ruled that Plaintiffs sufficiently alleged their claims and subsequently, their Motion to Dismiss based upon lack of standing was dismissed. This is specifically of note as typically when benefits have been exhausted, Medicare has not pursued recovery where a primary plan demonstrated that the policy had been exhausted.

The Court then turned to the argument that contract law would require dismissal. However, this position was unsuccessful as the Court held that 42 C.F.R § 411.24(e) could be enforced over State Farm’s contract argument and federal law supersedes state laws, regulations, contract requirements, or other standards that would otherwise apply to MAOs. In other words, a state cannot take away an MAO’s right under federal law and the MSP regulations to bill or to authorize providers and suppliers to bill for services for which Medicare is not the primary payer. This is a bit startling as in many similar cases the argument of state contract was wholly separate from the MSP Private Cause of Action provision. However, this departure in the District Court of Illinois could be the presage to the winds of change in these cases going forward.

Finally, the Court found State Farm’s Motion to Strike Class Allegations as premature. As a result, Recovery v. State Farm will continue to be litigated.

In summary, the ongoing rollercoaster that is MSP/MAO litigation is continuously keeping us on our toes. One case may provide victory for the recovery agents and one may not, but it is of the utmost importance to keep abreast of the constant litigation. Gordon & Rees will continue to vigilantly follow these cases and report accordingly.

Should you have any questions regarding the above or need any Medicare compliance assistance, please do not hesitate to contact Gordon & Rees Medicare Compliance Group. 

[1] Constitutional standing must exist at the time the lawsuit is filed.

CMS Issues Opioid Roadmap

On June 11, 2018, CMS issued a purported roadmap in the future handling of opioid medications. Appearing to build off the proposed processes announced in February of this year, CMS has detailed a three-pronged approach to combating the opioid crisis. This three-pronged approach consists of:

  • Prevention of new cases of opioid use disorder (OUD)
  • Treatment of patients who have already become dependent on or addicted to opioids
  • Utilization of data from across the country to target prevention and treatment activities

Furthermore, CMS reported that they have been working on communications with beneficiaries to explain the risk of prescription opioids. Another strategy, reported by CMS is to endeavor to work with individual states to tailor programs to their populations. Citing work with seven states, which were not expressly identified, CMS argues such a strategy could aid unique state populations and their individual issues with the opioid issue.

CMS admits this roadmap is only a start and the plans and programs will continue to evolve. We at Gordon & Rees will continue to monitor these proposed processes and will report any updates as they develop.

Pennsylvania’s Governor Wolfe Vetoes Workers’ Compensation Formulary Bill

Following in the footsteps of Texas, Ohio, and various other states, Pennsylvania’s legislature attempted to enact a drug formulary by amending the current Workers’ Compensation Act with Senate Bill 936. While passing in the House and Senate, Governor Tom Wolfe vetoed this proposed amendment.

Introduced on October 20, 2017 by various representatives, Bill 936 proposed that the department should select a nationally recognized, evidence-based prescription drug formulary for resolving issues related to drugs prescribed for or related to the treatment of work-related injuries. Expressly outlining a timeline in which comments would be taken, public notice of the formulary published, and when the final formulary would effect, Bill 936 also outlined the requirements to be considered when creating the prescription drug formulary.

After considerable debate and re-drafting, the bill was voted into the House and Senate on April 17, 2018. As indicated above, Governor Wolf then vetoed on April 27, 2018. Per a letter drafted by the Governor on May 27, 2018, Governor Wolfe noted “The implementation of a drug formulary as prescribed by this legislation will not improve overall health outcomes for Pennsylvania’s injured workers and will not stem the tide of the opioid crisis…many opioid medications are among the lease costly prescription medications on the market. Since the bill’s drug formulary is designed to steer physicians toward prescribing less costly drugs, it will not likely accomplish the often-stated objective of the bill’s promotors – curbing the opioid over-prescription.”

Interestingly, Governor Wolf’s rationale in vetoing the Bill was predicated on the fact that the formulary is aimed at cost-reduction and the limitation of opioids. However, per the language of the Bill itself this formulary was to be created after research and based upon evidence based medicine (which would most likely include the CDC’s recent recommendations regarding opioids), would be open for public comments which would arguably include injured workers’ and their advocacy groups, and would be reviewed yearly by the department based upon public comments received in November of each year. Admittedly, the Bill does state that the Pennsylvania Compensation Ratings Bureau shall calculate the savings achieved through the implementation of the prescription drug formulary, the assumption that the formulary is solely created for the cost-reduction of prescriptions in Workers Compensation claims appears to be faulty.

To further confuse the issue, Governor Wolf announced he signed an executive order aimed at curbing injured workers’ opioid prescriptions. Essentially mimicking much of the original Bill 936 directives, it is questionable whether such an order will be enforceable as state agencies do not have legal authority to limit prescription drugs on their own.

At the end of the day, Pennsylvania’s drug formulary has been tabled. However, several other states (i.e. Indiana and Massachusetts) have proposed legislation in place and are waiting on final voting. Although there is not much in the way of formal research on the benefits of drug formularies, the pioneer states like Texas, Ohio, and California have been implemented for a significant period of time and more empirical evidence of the benefits of such programs can be expected. Furthermore, this methodology is becoming increasingly more attractive to states in light of increasing insurance premiums and the opioid crisis. We at Gordon & Rees will continue to monitor the current legislation and report on any new developments.

 

 

Social Security Releases 2018 Trustee Report: Expect More Aggressive Measures from CMS.

On June 5, 2018, the Social Security Board of Trustees released it’s annual report on the long-term financial status of the Social Security Trust Funds.  Per this report, the Old—Age and Survivors Insurance and Disability Insurance (OASDI) Trust Funds are projected to become depleted in 2034 and Medicare by 2026. This projection remained the same from the previous year. More importantly, while the assets of the combined OASI Trust Funds increased by $44 billion in 2017, the total annual cost of the program is projected to exceed total annual income in 2018 for the first time since 1982, and remain higher throughout the 75-year projection period.

These figures are especially worrisome for those of us in the industry as Medicare has become increasingly more aggressive in recovery of payments, denial of payments, and garnishment of benefits. As the total annual cost of the program is expected to exceed the annual income, it is reasonable to conclude that more forceful tactics by the agency will be implemented to protect the Fund. Furthermore, civil penalties and other previously under utilized measures may be on the horizon. We at Gordon & Rees are committed to bringing you the most up to date information regarding this matter and will continue to report as new developments occur.